Axonics nets FDA approval for its rechargeable sacral neuromodulation implant

Axonics
About the size of a USB stick, the system’s miniaturized neurostimulator can be recharged wirelessly through the skin, compared to a similar device from Medtronic that needs to be surgically replaced every three to five years. (Image: Axonics)

Former FierceMedTech Fierce 15 winner Axonics Modulation Technologies has received FDA approval for its rechargeable neuromodulation implant to treat bowel dysfunction. 

According to the company, its r-SNM system has a functional life of 15 years and is compatible with full-body MRI scans.  

The approval covers the sacral neuromodulation device’s use in treating fecal incontinence; Axonics has an additional premarket approval filing currently under review at the FDA for overactive bladder and urinary retention.  

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“We believe the number of patients seeking SNM treatment will expand dramatically over the next few years given our fuss-free, long-lived, full-body MRI-compatible device,” Axonics CEO Raymond Cohen said in a statement.

“In the months prior to FDA approval, we invested significant time and resources in building inventory to support our fully trained, U.S. commercial team which now includes 145 territory managers, clinical support specialists and sales managers strategically located around the country,” Cohen said.

RELATED: FierceMedTech’s 2017 Fierce 15 | Axonics

“We plan to begin shipping product to U.S. physicians and hospitals during the fourth quarter of 2019, following the fulfillment of customary, pre-launch regulatory requirements,” he added.

About the size of a USB stick, the system’s miniaturized neurostimulator can be recharged wirelessly through the skin, compared to a similar device from Medtronic that needs to be surgically replaced every three to five years. 

It also includes a patient remote control and a programmer for clinicians to facilitate lead placement and stimulation. By delivering electrical stimulation to the body’s sacral nerve, the device aims to correct erroneous signals sent between the bowels, bladder and brain.

Last November, Axonics pulled off a $120 million IPO, following a $40 million funding round the April before. The company has already secured approvals for its device across Europe, Canada and Australia.

Suggested Articles

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

The drug, Compass Pathways’ COMP360, came through the placebo-controlled phase 1 without setting off any safety alarms.

Kite hopes to win approval for KTE-X19 in mantle cell lymphoma on the strength of midphase results linking it to a 67% complete response rate.